Extreme prematurity remains a major cause of neonatal mortality and severe long‐term
morbidity. Current neonatal care is associated with significant morbidity due to iatrogenic …

Artificial placenta and artificial womb technologies to support extremely premature neonates
are advancing toward clinical testing in humans. Currently, no recommendations exist …

Abstract The so called “Artificial Placenta” and “Artificial Womb”(EXTEND) technologies
share a common goal of improving outcomes for extreme premature infants. Beyond that …

Background Ex vivo uterine environment therapy is an experimental life support platform
designed to reduce the risk of morbidity and mortality for extremely preterm infants born at …

Background Clinical translation of the extracorporeal artificial placenta (AP) is impeded by
the high risk for intracranial hemorrhage in extremely premature newborns. The Nitric Oxide …

Artificial placenta (AP) technology aims to maintain fetal circulation, while promoting the
physiologic development of organs. Recent reports of experiments performed in sheep …

Early preterm birth< 34 gestational weeks (GA) and birth weight (BW)< 2 kg are relative
contraindications for extracorporeal membrane oxygenation (ECMO). However, with …

Despite significant advances in the treatment of prematurity, premature birth results in
significant mortality and morbidity. In particular, extremely low gestational age newborns …

The use of extracorporeal life support (ECLS) for the pediatric and neonatal population
continues to grow. At the same time, there have been dramatic improvements in the …

The recent demonstration of normal development of preterm sheep in an artificial
extrauterine environment has renewed interest in artificial placenta (AP) systems as a …